Skip to main content
IDYA
NASDAQ Life Sciences

IDEAYA Halts Phase 3 Eye Cancer Trial, Frees $100-125M for ADC Push

Tom Rudovsky · Reported by PR Newswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$31.64
Mkt Cap
$3.053B
52W Low
$26.81
52W High
$42.68
52W Position info
18% above low
Off High info
26% below high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

IDYA sits 18% above its 52-week low of $26.81.

Summary

IDEAYA closed out Q3 with $1.15 billion in cash and kept its runway guidance into 2030 unchanged, but the bigger news is the decision to stop enrollment and shut the Phase 3 OptimUM-010 trial in neoadjuvant uveal melanoma due to site activation and enrollment problems. Management expects that to free up $100-125 million, which it will redirect to potential registrational trials for IDE849 and IDE892. The darovasertib NDA in metastatic uveal melanoma was submitted in Q3 under the FDA's Real-Time Oncology Review program, and ESMO data presented in October support the combination across HLA status and lines of therapy. Quarterly R&D rose to $121.6 million from $108.7 million and the net loss widened to $125.7 million from $112.5 million, with a loss per share of $1.22 and revenue of $10.2 million, so spending is climbing even as one late-stage program is cut. The company also promoted Dr. Michael White to President, Research and Development, and will host an R&D Day in London on November 16, 2026 to lay out the MTAP/CDKN2A combination strategy with RAS inhibitors.

At the time of this announcement, IDYA was trading at $31.64 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.1B. The 52-week trading range was $26.81 to $42.68. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: PR Newswire.


Price Chart

Share this article

Copied!

IDYA - Latest Insights

IDYA
Nov 03, 2026, 4:00 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $31.36
Real-time Price: $26.17 info
Change: -$5.19 (-17%) info
Market Cap: $2.53B info
IDYA
Oct 19, 2026, 7:08 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $33.50
Real-time Price: $26.17 info
Change: -$7.33 (-22%) info
Market Cap: $2.53B info
IDYA
Aug 19, 2026, 6:00 AM EDT
Source: PR Newswire
Importance Score:
7
Price at Filing: $37.93
Real-time Price: $26.17 info
Change: -$11.76 (-31%) info
Market Cap: $2.53B info
IDYA
Aug 04, 2026, 4:05 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $36.11
Real-time Price: $26.17 info
Change: -$9.94 (-28%) info
Market Cap: $2.53B info
IDYA
Aug 04, 2026, 6:01 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $35.40
Real-time Price: $26.17 info
Change: -$9.23 (-26%) info
Market Cap: $2.53B info